TW200413324A - Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof - Google Patents

Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof Download PDF

Info

Publication number
TW200413324A
TW200413324A TW092127799A TW92127799A TW200413324A TW 200413324 A TW200413324 A TW 200413324A TW 092127799 A TW092127799 A TW 092127799A TW 92127799 A TW92127799 A TW 92127799A TW 200413324 A TW200413324 A TW 200413324A
Authority
TW
Taiwan
Prior art keywords
dihydro
dibenzo
hydroxy
carboxamide
doc
Prior art date
Application number
TW092127799A
Other languages
English (en)
Chinese (zh)
Inventor
Christian Mathes
Gottfried Sedelmeier
Fritz Blatter
Sabine Pfeffer
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200413324A publication Critical patent/TW200413324A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW092127799A 2002-10-07 2003-10-07 Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof TW200413324A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds

Publications (1)

Publication Number Publication Date
TW200413324A true TW200413324A (en) 2004-08-01

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092127799A TW200413324A (en) 2002-10-07 2003-10-07 Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide and new crystal forms tmereof

Country Status (20)

Country Link
US (1) US20060142566A1 (cg-RX-API-DMAC10.html)
EP (1) EP1551808A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006504710A (cg-RX-API-DMAC10.html)
KR (1) KR20050071549A (cg-RX-API-DMAC10.html)
CN (2) CN101062932A (cg-RX-API-DMAC10.html)
AR (1) AR041544A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003276055B2 (cg-RX-API-DMAC10.html)
BR (1) BR0315113A (cg-RX-API-DMAC10.html)
CA (1) CA2501237A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP055738A (cg-RX-API-DMAC10.html)
GB (1) GB0223224D0 (cg-RX-API-DMAC10.html)
HK (1) HK1079790A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05003737A (cg-RX-API-DMAC10.html)
NO (1) NO20052244L (cg-RX-API-DMAC10.html)
PE (1) PE20040686A1 (cg-RX-API-DMAC10.html)
PL (1) PL376379A1 (cg-RX-API-DMAC10.html)
RU (1) RU2005114350A (cg-RX-API-DMAC10.html)
TW (1) TW200413324A (cg-RX-API-DMAC10.html)
WO (1) WO2004031155A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502561B (cg-RX-API-DMAC10.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) * 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
IN2015DN02296A (cg-RX-API-DMAC10.html) 2012-09-26 2015-08-21 Ranbaxy Lab Ltd
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9029540B2 (en) * 2013-07-01 2015-05-12 Boehringer Ingelheim International Gmbh Ruthenium catalysts and their use for asymmetric reduction of ketones
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
CA2374553A1 (fr) * 1999-06-15 2000-12-21 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
ES2211373T1 (es) * 2001-02-12 2004-07-16 Teva Pharmaceutical Industries Ltd. Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.

Also Published As

Publication number Publication date
CA2501237A1 (en) 2004-04-15
HK1079790A1 (zh) 2006-04-13
GB0223224D0 (en) 2002-11-13
PL376379A1 (en) 2005-12-27
RU2005114350A (ru) 2006-01-20
US20060142566A1 (en) 2006-06-29
PE20040686A1 (es) 2004-10-29
NO20052244L (no) 2005-07-07
BR0315113A (pt) 2005-08-23
CN101062932A (zh) 2007-10-31
ECSP055738A (es) 2005-07-06
KR20050071549A (ko) 2005-07-07
JP2006504710A (ja) 2006-02-09
ZA200502561B (en) 2006-02-22
AU2003276055B2 (en) 2008-01-03
NO20052244D0 (no) 2005-05-06
AU2003276055A1 (en) 2004-04-23
EP1551808A1 (en) 2005-07-13
MXPA05003737A (es) 2005-06-17
AR041544A1 (es) 2005-05-18
CN1703404A (zh) 2005-11-30
WO2004031155A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2003276055B2 (en) Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof
CA2837727C (en) Substituted imidazopyridinyl-aminopyridine compounds
TWI461410B (zh) 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類
AU2012270029B2 (en) Compositions and methods for modulating a kinase
CA2785716A1 (en) Substituted pyrrolo-aminopyrimidine compounds
PT2032575E (pt) NOVO DERIVADO DE 1,4-DIAZA-BICICLO[3,2,2]NONIL-OXADIAZOLILO E A SUA APLICAÆO MéDICA
JP3429338B2 (ja) 新規なアリールグリシンアミド誘導体及びその製造法
WO2012177852A1 (en) Substituted imidazopyridinyl compounds
CA2756870A1 (en) Substituted indolo-pyridinone compounds
JP4748320B2 (ja) 環状アミン誘導体又はその塩
JP2018525377A (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
WO1995033455A1 (en) Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
JP3476193B2 (ja) 置換ヘキサヒドロベンゾ〔α〕フェナンスリジン類
CN101855223A (zh) 新的1,4-二氮杂-二环[3.2.2]壬基嘧啶衍生物及它们的医药应用
CN103833756A (zh) 一类哒嗪酮类化合物及其制备方法和用途
JP7286001B2 (ja) 第ＸＩａ因子阻害剤としての大環状誘導体
CN101970438A (zh) 新的1，4-二氮杂-二环[3.2.2]壬基嘧啶衍生物及它们的医药应用
TW201100424A (en) Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
EP1219619A1 (en) Piperidine derivatives
CA2756809A1 (en) Substituted tetrahydropyrazolo-pyrido-azepin compounds
TW202444709A (zh) 短肽類化合物及其製備方法和醫藥應用
TW202604903A (zh) 作為kras抑制劑的稠合吡啶酮類化合物的製備方法、中間體及其製備方法
CN116693470A (zh) 组胺h3受体抑制剂及其医药用途
TW202545925A (zh) 螺環kif18a抑制劑
Moorthy et al. Pharmaceutical Co-Crystals of Methylparaben with Api Drugs: Synthesis, Spectroscopic Characterization, and Solid-State Properties